FIC20240009I1 - Kitsartinibi - Google Patents

Kitsartinibi

Info

Publication number
FIC20240009I1
FIC20240009I1 FIC20240009C FIC20240009C FIC20240009I1 FI C20240009 I1 FIC20240009 I1 FI C20240009I1 FI C20240009 C FIC20240009 C FI C20240009C FI C20240009 C FIC20240009 C FI C20240009C FI C20240009 I1 FIC20240009 I1 FI C20240009I1
Authority
FI
Finland
Prior art keywords
kitsartinib
Prior art date
Application number
FIC20240009C
Other languages
English (en)
Finnish (fi)
Original Assignee
Ambit Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Biosciences Corp filed Critical Ambit Biosciences Corp
Publication of FIC20240009I1 publication Critical patent/FIC20240009I1/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
FIC20240009C 2009-05-14 2024-03-27 Kitsartinibi FIC20240009I1 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17847209P 2009-05-14 2009-05-14
US24397709P 2009-09-18 2009-09-18
PCT/US2010/034926 WO2010132787A1 (fr) 2009-05-14 2010-05-14 Méthodes de traitement de maladies prolifératives

Publications (1)

Publication Number Publication Date
FIC20240009I1 true FIC20240009I1 (fi) 2024-03-27

Family

ID=42289326

Family Applications (1)

Application Number Title Priority Date Filing Date
FIC20240009C FIC20240009I1 (fi) 2009-05-14 2024-03-27 Kitsartinibi

Country Status (18)

Country Link
US (2) US8865710B2 (fr)
EP (1) EP2429524B1 (fr)
AU (2) AU2010248860B2 (fr)
CA (1) CA2761940C (fr)
CY (1) CY1122765T1 (fr)
DK (1) DK2429524T3 (fr)
ES (1) ES2773315T3 (fr)
FI (1) FIC20240009I1 (fr)
HR (1) HRP20200255T1 (fr)
HU (2) HUE048309T2 (fr)
LT (1) LT2429524T (fr)
NL (1) NL301265I2 (fr)
NO (1) NO2024011I1 (fr)
NZ (1) NZ596739A (fr)
PL (1) PL2429524T3 (fr)
PT (1) PT2429524T (fr)
SI (1) SI2429524T1 (fr)
WO (1) WO2010132787A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2646437C (fr) * 2006-03-17 2016-05-17 Ambit Biosciences Corporation Composes d'imidazolothiazole pour le traitement de maladies
EP2410987B1 (fr) 2009-03-23 2018-05-16 Ambit Biosciences Corporation Procédés de traitement utilisant une multithérapie
JP6116847B2 (ja) 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションAmbit Biosciences Corporation シクロデキストリンとの混合体を含有する錠剤
CN104513252B (zh) * 2013-09-26 2017-11-10 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
EP3191187B1 (fr) 2014-09-09 2021-07-28 Janssen Biotech, Inc. Polythérapies avec des anticorps anti-cd38
KR102597989B1 (ko) * 2014-12-04 2023-11-02 얀센 바이오테크 인코포레이티드 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체
TWI711452B (zh) 2015-02-20 2020-12-01 日商第一三共股份有限公司 癌症的倂用治療法
MX2017014810A (es) 2015-05-20 2018-05-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
IL256242B1 (en) 2015-06-22 2024-05-01 Janssen Biotech Inc Combination therapies for HEME malignancies with anti-CD38 antibodies and sorbibin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
ES2912729T3 (es) 2015-11-03 2022-05-27 Janssen Biotech Inc Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
AU2018359527A1 (en) 2017-10-31 2020-05-07 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
CA2646437C (fr) 2006-03-17 2016-05-17 Ambit Biosciences Corporation Composes d'imidazolothiazole pour le traitement de maladies
EP2201018B1 (fr) 2007-09-19 2016-03-16 Ambit Biosciences Corporation Formes solides comprenant de la n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-ý7-(2-morpholin-4-yl-éthoxy)imidazoý2,l-b¨ýl,3¨benzothiazol-2-yl¨phényl}urée, compositions en contenant et leurs utilisations
KR20150105494A (ko) * 2007-11-08 2015-09-16 암비트 바이오사이언시즈 코포레이션 증식성 질환을 치료하기 위하여 n-(5-tert-부틸-아이소제이졸-3-일)-n′-{4-[7-(2-몰포린-4-일-에톡시)이미다조[2,1-b][1,3]벤조티아졸-2-일]페닐}우레아를 투여하는 방법
EP2358725A1 (fr) * 2008-11-06 2011-08-24 Ambit Biosciences Corporation Composés imidazolothiazoles utilisés comme modulateurs de protéine kinases
EP2410987B1 (fr) 2009-03-23 2018-05-16 Ambit Biosciences Corporation Procédés de traitement utilisant une multithérapie
EP2496584B1 (fr) 2009-11-05 2016-09-21 Ambit Biosciences Corporation Procédé de préparation de dérivés d'imidazo[2,1-b][1,3]benzothiazole
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションAmbit Biosciences Corporation シクロデキストリンとの混合体を含有する錠剤

Also Published As

Publication number Publication date
EP2429524A1 (fr) 2012-03-21
US9555040B2 (en) 2017-01-31
WO2010132787A1 (fr) 2010-11-18
AU2015230806A1 (en) 2015-10-15
CA2761940A1 (fr) 2010-11-18
ES2773315T3 (es) 2020-07-10
AU2010248860A1 (en) 2011-12-22
US20120258081A1 (en) 2012-10-11
EP2429524B1 (fr) 2020-01-15
CA2761940C (fr) 2018-04-10
NL301265I1 (nl) 2024-03-20
HUS2400008I1 (hu) 2024-04-28
LT2429524T (lt) 2020-05-11
CY1122765T1 (el) 2021-03-12
HUE048309T2 (hu) 2020-07-28
US20160051557A1 (en) 2016-02-25
US8865710B2 (en) 2014-10-21
NZ596739A (en) 2014-01-31
DK2429524T3 (da) 2020-02-24
NL301265I2 (nl) 2024-06-05
NO2024011I1 (no) 2024-03-14
PL2429524T3 (pl) 2020-08-24
HRP20200255T1 (hr) 2020-09-04
SI2429524T1 (sl) 2020-07-31
AU2010248860B2 (en) 2015-06-25
PT2429524T (pt) 2020-03-02

Similar Documents

Publication Publication Date Title
FIC20240009I1 (fi) Kitsartinibi
DE112010004215A5 (de) Hydrostataktor
DE112010002949A5 (de) Kupplungstastpunkte
BRPI1008827A2 (pt) deisobutenizador
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
DE112010004249A5 (de) Spindelaktor
DE112009005323A5 (de) Hebelarmprüfmaschine
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BR112012004964A2 (pt) girocóptero
BRPI1008070A2 (pt) tricianoboratos
DK2483126T3 (da) Skinnekøretøj
DK2506968T3 (da) Faujasit-zeolit
DE112010004865T8 (de) Lamellennassreibkupplung
DE112010003255A5 (de) Fördergutverteiler
BRPI1010159A2 (pt) bistuti
DE602010000025D1 (de) Fahrzeugsitzgurtvorrichtung
FI20090100A0 (fi) Biotinidaasimääritys
BR112012003616A2 (pt) metilpirroloprimidinacarboxamidas
DE112010002351A5 (de) Klemmorrichtung
DE112010003843T8 (de) Lastansteuervorrichtung
DE202009005065U8 (de) Kartonverschließmaschine
DE102009034429A8 (de) Flachantenne
DE112010004370A5 (de) Solarkollektorsystern
ES1071436Y (es) Marquesina autoportante